Stoke un­veils new da­ta on ge­net­ic epilep­sy drug — and in­vestors are stoked

Stoke Ther­a­peu­tics’ treat­ment for Dravet syn­drome — a rare, ge­net­ic epilep­sy that be­gins in in­fan­cy — helped re­duce seizures in an ear­ly-stage study.

The treat­ment al­so led …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER